Contrave with varying doses causes 7-8% weight loss in six months, 8-9% in nine months

Posted by .(JavaScript must be enabled to view this email address)
Friday, March 30, 2007 2:12 am Email this article
Among patients who finished the study, those given Contrave, with higher than 300 mg doses of Wellbutrin (bupropion) and one of three different doses of naltrexone -- I assume less than 50 mg used in the previous study in order to try and reduce nausea -- lost an average of 7 percent to 7.6 percent after six months compared to 1.1 percent for those given a placebo. After nine months, the average weight loss for those still in the study was 8 percent to 9.3 percent. 6 Month Weight Loss

6 month weight Loss for all patients: 4.3% to 5.4% after six months, 4.6% to 6.1% after nine months

Among all patients treated, including those who dropped out of the study early, the average weight loss in the three groups of people given Contrave was 4.3 percent to 5.4 percent after six months compared to 0.8 percent for those given a placebo.

 

6 Month Weight Loss

9 month weight Loss for all patients: 4.6% to 6.1% after nine months

Among all patients treated, including those who dropped out of the study early, after nine months, the average weight loss in the three groups of people given Contrave was 8 percent to9.3 percent.

 

Doses

Doses: More than 300 mg of Wellbutrin plus more than 50 mg of naltrexone

The dose of Wellbutrin (bupropion) used in this study was more than 300 mg used in the previous study, although I don’t know exactly dose of Wellbutrin (bupropion) used in this study.

This higher dose of Wellbutrin (bupropion) was combined with three different doses of immediate-release naltrexone.

I don’t know the exact doses of naltrexone used in this study, however, I assume they were less than the 50 mg used in the previous study in order to try and reduce the high incidence of nausea.

 

Side Effects

Side Effects: I don’t know how many reported nausea

I don’t know the percentage of patients who reported nausea in this study, although they did note that lower doses of naltrexone cause less nausea.

In their previous study, which used 50 mg of naltrexone, 40 percent of patients reported nausea which was due to the naltrexone.

 

Dropouts

Dropouts:  I don’t know how many dropped out due to nausea

I don’t know the percentage of patients who dropped out of this study, however, in their previous study, which used 50 mg of naltrexone, approximately one-out-of-eight patients (12 percent) dropped out of the study due to nausea.

 

Subjects

Subjects: 250 patients

This study involved 250 people at 14 sites.

 

Company Info

Contrave being developed by Orexigen Therapeutics

Contrave is being developed as a weight loss drug by a company in San Diego, California called Orexigen Therapeutics, the same company that is developing Excalia, which is a combination of Wellbutrin (bupropion) and Zonegran (zonisamide).

REFERENCE

OREXIGEN reports positive 24-week results for Contrave phase III obesity treatment study. Press Release, 2006 Sept 26.

Contact Information of Orexigen Therapeutics

Orexigen Therapeutics, Inc.
12481 High Bluff Drive, Suite 160
San Diego, CA 92130

858-436-8600 phone
858-436-8650 fax
.(JavaScript must be enabled to view this email address)
Data on Orexigen’s Clincal Trials

Articles on the same subject can be found here:

• Contrave (Wellbutrin (bupropion) plus naltrexone)

• Wellbutrin (bupropion)